Soligenix Inc

Soligenix’s Phase 2a wins for SG 945 in Behçet’s disease and SG 302 for psoriasis hint at orphan‑drug status and a new topical market, raising investor interest and potential upside.

Soligenix Inc.’s stock price surged 260% after the biotechnology company announced positive results from a clinical trial of its treatment for Behçet’s Disease, a chronic inflammatory disorder.

Soligenix Inc. has successfully transferred its synthetic hypericin manufacturing process to the US, positioning the biotech company for growth in the GPCR-targeting therapies market.